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ABSTRACT
Background/aims: Mutations in ABCA4 have been
associated with autosomal recessive Stargardt disease
(STGD), a few cases with autosomal recessive cone–rod
dystrophy (arCRD) and autosomal recessive retinitis
pigmentosa (arRP). The purpose of the study was
threefold: to molecularly characterise families with no
mutations or partially characterised families; to determine
the specificity and sensitivity of the genotyping micro-
array; and to evaluate the efficiency of different
methodologies.
Methods: 23 STGD, five arCRD and three arRP Spanish
patients who were previously analysed with the ABCR400
microarray were re-evaluated. Results were confirmed by
direct sequencing. In patients with either none or only one
mutant allele, ABCA4 was further analysed by denaturing
high-performance liquid chromatography (dHPLC) and
multiplex ligation-dependent probe amplification (MLPA).
Haplotype analysis was also performed.
Results: In the first analysis performed with the
microarray, 27 ABCA4 variants (27/62; 43.5%) were
found. By dHPLC scanning, 12 novel mutations were
additionally identified. In addition, two previously
described mutations, one false negative (1/62; 1.6%) and
one false positive (1.6%), were detected. MLPA analysis
did not reveal additional substitutions. The new strategy
yielded an increment of 21% compared with the approach
used in the first round.
Conclusion: ABCA4 should be analysed by optimal
combination of high-throughput screening techniques
such as microarray, dHPLC and direct sequencing. To the
best of our knowledge, this strategy yielded significant
mutational spectrum identification in Spanish patients
with ABCA4-associated phenotypes. Follow-up of
patients, presenting an early onset of the disease and
severe mutations, seems essential to perform accurate
genotype–phenotype correlations and further character-
isation of pathological ABCA4 alleles.
Stargardt disease (STGD, MIM #248200) is the
most common hereditary macular dystrophy, with
an estimated prevalence of 1:10 000.
1 It is
characterised by onset in the juvenile to young
adult years, decreased central vision, progressive
bilateral atrophy of the retinal pigment epithelium
(RPE) and the appearance of orange-yellow flecks
around the macula and/or mid-periphery of the
retina.
2
The locus for recessive STGD was mapped to
chromosome 1 (1p21–p13).
3 Mutations in ABCA4
have been described in autosomal recessive STGD
(arSTGD),
4 autosomal recessive retinitis pigmen-
tosa (arRP),
5 autosomal recessive cone–rod dystro-
phy (arCRD)
6 and age-related macular
degeneration (AMD).
7
Up to now, ,500 disease-causing mutations
have been identified in ABCA4. The mutation
spectrum ranges from single base substitutions to
deletions of several exons, although the majority of
reported changes are missense mutations. As has
been described, mutations in this gene account for
66–80% of STGD-associated chromosomes.
89
Despite all the efforts of many research teams,
there is a variable mutation detection rate, and this
is often not satisfactory because there are still
many undiscovered mutations. Therefore, the
combination of different technical approaches,
together with knowledge of the genetic back-
ground for a given population is important for
the determination of novel mutations and for the
genetic characterisation of these patients.
METHODS
Recruitment of subjects
A subset of Spanish STGD, arCRD and arRP
patients previously tested for variants on the
ABCR400 genotyping microarray described by
Jaakson et al,
10 in whom none or only one allele
could be identified, was selected for further
analysis. This molecular study was reviewed and
approved by the Ethics Committee of the Hospital
(Fundacion Jimenez Diaz) and adhered to the
tenets of the Declaration of Helsinki (http://
www.wma.org). Informed consent was obtained
from all patients after the nature of procedures to
be performed was fully explained.
Clinical evaluation
Diagnoses of STGD, arCRD and arRP were
determined according to a recessive mode of
inheritance and were based on the following
criteria:
c Diagnosis of STGD was determined according
to a bilateral central vision loss with a beaten-
bronze appearance and/or the presence of
orange-yellow flecks in the retina from the
posterior pole to the mid-periphery; typical
dark choroid observed by fluorescein angiogra-
phy; and normal to subnormal electroretino-
grams (ERGs).
c Diagnosis of CRD was based in initial com-
plaints of blurred central vision without a
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colour vision, funduscopic evidence of atrophic macular
degeneration, peripheral disturbances including pigment
clumping and/or pigment epithelial thinning, and greater
or earlier loss of cone than rod ERG amplitude.
c RP was diagnosed in patients who developed night blindness
early in life, peripheral vision loss, pigmentary retinal
degeneration and markedly reduced scotopic ERG.
MOLECULAR METHODS
DNA extraction
Peripheral blood samples were taken, and genomic DNA was
extracted using an automated DNA extractor (BioRobot EZ1,
Qiagen, Hilden, Germany).
Genotyping microarray
DNA samples from patients were analysed for variants on the
ABCR400 microarray (http://www.asperbio.com), as described
elsewhere.
10 The 50 exons of the ABCA4 gene, including the
intron–exon junctions, were amplified using previously
described PCR primers.
11
Direct sequencing
The sequencing reaction was performed with the Big-dye DNA
Sequencing Kit (Applied Biosystems, Foster City, California).
Sequence products were resolved in an ABIPrism 3130 (Applied
Biosystems).
Denaturing high-performance liquid chromatography
Denaturing high-performance liquid chromatography (dHPLC)
sample screening was performed on a WAVE DNA Fragment
Analysis System (Transgenomic). Because dHPLC does not
usually differentiate the wild-type from the homozygous
mutant sample, all unknown samples were analysed both
singularly and mixed in a 1:1 proportion with a wild-type
sample at the end of each PCR session and before heteroduplex
formation.
Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA)
reagents were obtained from MRC-Holland (SALSA MLPA kit
P151-P152 ABCA4, Amsterdam), and the reactions were
performed according to the manufacturer’s instructions
(MRC-Holland).
Fluorescent-PCR
In order to assess the size of one duplication found in exon 40 of
the ABCA4 gene, the PCR product was analysed in the ABIPrism
3130 (Applied Biosystems).
Restriction assays
The presence of one novel missense mutation (p.Ile2047Asn)
was analysed in 100 control chromosomes by conventional PCR
amplification, restriction enzyme digestion (37uC overnight)
with TaqI and analyses of the restriction fragments in a 3%
agarose gel.
Haplotype analysis
Haplotypes were constructed using three microsatellite markers
flanking the ABCA4 gene (TEL-D1S435-D1S2804-ABCA4-D1S236-
CEN). Amplicons were electrophoresed using an ABIPrism
3130 (Applied Biosystems). For haplotype reconstruction, a
computer program was used (Cyrillic version 2.1; http://
www.cyrillicsoftware.com).
Bioinformatics tool
In order to establish the nature of the variants located in the
introns of the ABCA4 gene, wild type and mutated sequences
were analysed with Prediction Servers of Intron Splice Sites in
human (Center for Biological Sequence Analysis of University of
Denmark (http://www.cbs.dtu.dk/services)).
RESULTS
Molecular analysis
Further analysis of partially characterised families and identification
of novel variants
A total of 31 Spanish patients, who were previously tested for
mutations with the ABCR400 microarray, were further
analysed with two different techniques: dHPLC and MLPA. In
27 out of 31 patients, only one disease-associated allele was
detected using the genotyping microarray, and in the remaining
cases, no variant was detected by the chip (four out of 31
patients). Therefore, the mutation detection rate for the
microarray was 43.5%. However, a subsequent analysis
performed by dHPLC (fig 1) led to the identification of 24
sequence variations in the ABCA4 gene (tables 1, 2).
Eight of these changes were interpreted as null mutations:
three were nonsense mutations (p.Gln234X, p.Gln1315X ‘‘de
novo’’ and p.Gln2187X); two splice-site mutations (IVS22-
2A.T and IVS38+5G.A); three frameshift variants: two
caused by the insertion or deletion of one nucleotide
(c.1029_1030insT and c.4739delT) and one duplication of five
amino acids (p.KNLFA1876dup). We were able to determine
that this duplication was of maternal inheritance (fig 2). Three
missense changes were detected (p.Ala762Glu, p.Ile2047Asn and
p.Cys2137Tyr) in patients but not in the 100 ethnically
matched control chromosomes. We identified the heterozygous
p.Ile2142Val change in one out of 100 control chromosomes.
Interestingly, this variant has not been previously described and
was not found in Spanish STGD/CRD patients. Moreover, two
previously described mutations [c.4537delC and p.Trp1724Cys],
not included in the array by the time of the screening, and one
false negative [p.Gly1977Ser] were detected (1/62; 1.6%).
Despite these putative disease-associated alleles, additional
variants interpreted as non-pathogenic were identified.
Additionally, one novel change in exon 12 (p.Val552Ile) was
found in one STGD patient by means of the dHPLC technique.
This variant was detected in two alleles out of 200, suggesting a
polymorphism. We also found six variants that did not produce
a change at the protein level, five being novel ones and eight
intronic variants, three of them previously unreported (table 2).
These three changes located in the introns were analysed with a
bioinformatics tool. According to this analysis, these variants
are not predicted to affect the splicing process.
Finally, in 17 of 31 patients in whom the second mutant allele
or no disease-associated alleles were found, we assessed dosage
for the ABCA4 locus using the MLPA technique. No deletions or
duplications were found for any of the 48 amplified probes in
these cases. These results were compared with two control
samples.
Despite the high allelic heterogeneity and the large amount of
novel ABCA4 variants detected in this screening, the
p.Arg1129Leu mutation was found to be the most frequent
disease-associated allele (5/62; 8%).
Clinical science
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samples from additional family members were available. In 11
STGD families and one CRD family, where an additional
pathogenic change was found, correct segregation of the disease
alleles was demonstrated (fig 3). Haplotype analysis was also
performed, and cosegregation was observed (available on
request).
The combination of direct sequencing, together with dHPLC
and MLPA techniques allowed us to further analyse the ABCA4
gene in STGD, arCRD and arRP cases, therefore leading to the
identification of 21 novel sequence variants. In addition, the
specificity, sensitivity and efficiency of different methodologies
were evaluated.
Determination of sensitivity and specificity of the ABCR400
microarray
We identified 1.6% (1/62) of false positives and 1.6% (1/62) of
false negatives for the ABCR400 microarray. In the patient
belonging to family ARDM-197, the chip detected the
p.Ala1598Asp mutation. However, dHPLC and direct sequen-
cing demonstrated that this mutation was not present (false
positive). Interestingly, the p.Trp1724Cys mutation was
detected by dHPLC in this family. In contrast, the dHPLC
technique led to the detection of the p.Gly1977Ser mutation in
the patient from the family ARDM-183, but the chip did not
detect it (false negative). Therefore, the values of sensitivity and
specificity of the genotyping microarray were 96.3% and 97.1%,
respectively.
Evaluation of the efficiency of different methodologies
The genotyping microarray identified a total of 27 disease-
associated alleles, yielding a mutation detection rate of 43.5%.
As we currently confirm these results by sequencing, a false
positive [p.Ala1598Asp] was identified. Altogether, the combi-
nation of several high-throughput approaches—ABCR400
microarray, dHPLC, MLPA and direct sequencing as a con-
firmation method—led to the detection of 12 novel mutations
and one false negative. Therefore, the detection rate was
increased by 21%, mainly due to dHPLC scanning, achieving a
mutation detection rate of 64.5% (40/62). Moreover, two
previously described pathogenic variants were also detected. In
addition, nine novel polymorphisms were identified.
Genotype–phenotype correlation
STGD patients presenting one putative null allele
Importantly, putative null mutations—including frameshifts,
nonsense, or splice-site variants—were observed more fre-
quently (7/31 patients; 22.6%) in compound heterozygous
alleles from patients with age of onset of the disease ,10 years,
all of them presenting a STGD phenotype (table 1). A total of 13
putative null disease-associated alleles (13/62; 20.9%) were
identified in this study. The majority of patients who presented
at least one putative null mutation presented early-onset
symptoms, except for two STGD patients belonging to the
families ARDM-135 and ARDM-225, whose disease started at
the age of 24–25 years. Moreover, both patients presented the
p.Gly1961Glu mutation, which is considered an allele of
moderate effect.
7
Figure 1 Chromatograms showing differences between the wild-type (down) and mutated profile (up). The wild-type sample shows a single peak, but
the mutated sample shows different peaks. In some cases, the difference between chromatograms is very significant (B, C and D); in other cases, it is
not so (A). Nevertheless, these samples were confirmed by sequencing for all family members.
Clinical science
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Patients from families ARDM-125 and ARDM-158 were
carrying two putative null ABCA4 alleles (table 1). Both of
them harboured the previously reported c.3211insGT mutation.
For the second disease-associated allele, the patient from family
ARDM-125 showed a duplication of five amino acids
(p.KNLFA1876dup), while the patient from family ARDM-158
presented the frameshift c.4537delC mutation. Probands from
these families presented a STGD phenotype, presenting
symptoms since the age of 9.
Patients presenting arCRD and arRP phenotypes
Interestingly, in our patients with arCRD and arRP phenotypes,
no putative null mutations were found (table 1). In three arRP
cases, the second disease-associated allele was not identified. In
one of them, cosegregation of the mutation within the family
was observed.
DISCUSSION
Thirty-one Spanish families were analysed for mutations in
ABCA4. This gene encodes the ABCA4 protein, a member of the
ATP-binding cassette (ABC) transport super-family. It is
involved in the transport of vitamin A derivates across the
membrane of the outer segment discs of photoreceptors.
12 13
The frequency of mutated alleles found with the microarray
was 43.5% (27/62; 33.8% (21/62) for STGD patients, 4.8% (3/
62) for arCRD patients and 4.8% (3/62) for arRP patients).
However, the frequency of mutated alleles detected with
microarray and dHPLC was 54.8% (34/62) for STGD patients
and 6.4% (4/62) for arCRD patients. In contrast, the mutation
detection rate for arRP cases was not increased by dHPLC
scanning, as no additional disease-associated alleles were found.
Table 2 Synonymous and non-synonymous codon variants and intronic
variants in the ABCA4 gene
Exon Nucleotide change Sequence change Reference
3 c.264 A.T p.Gly88Gly This study
IVS2-27G.A This study
IVS3+26 A.G
91 51 8
IVS6-32 T.C
91 5
8 c.1029T.C p.Asn343Asn This study
10 c.1299A.G p.Glu433Glu This study
12 c.1654G.A p.Val552Ile This study
IVS13+16G.A This study
19 c.2832A.G p.Pro944Pro This study
20 c.2964C.T p.Leu988Leu
18
23 c.3507G.A p.Gln1169Gln This study
IVS28+43G.A
24
IVS43-16G.A
25
IVS48+39 T.A This study
IVS48-3T.C
15 18
Novel changes are shown in bold.
Figure 2 Electropherogram showing the five-amino-acid duplication (p.KNLFA1876dup) in the patient from family ARDM-125. By this design, we
could confirm that this gain was of maternal origin.
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frequent missense variant, representing 8% (5/62) of the total
pathogenic alleles (table 1). In previous studies of the Spanish
population, the p.Arg1129Leu variant was identified as a major
mutant allele which accounted for 24% of the STGD alleles.
14
This variant has been postulated to have a moderately severe
effect and has predominantly been associated with a STGD
phenotype.
14 In contrast, the prevalence of this mutation in
patients from North America was less than 1%.
15 Interestingly,
we identified one 30-year-old patient (ARDM-247), double
heterozygous for the p.Arg1129Leu and p.Cys2137Tyr alleles,
who presented a CRD phenotype. This p.Cys2137Tyr change
was located more towards the amino terminus. Moreover, in
other study, the results showed that the changes located in this
zone appear to result in altered processing of the protein and to
be associated with an earlier onset of disease.
16 The
p.Cys2137Tyr change in combination with the p.Arg1129Leu
allele produced a CRD phenotype. Therefore, we speculate that
the novel p.Cys2137Tyr variant could be a severe allele which is
modifying the patient’s phenotype.
The second most prevalent missense disease-associated allele
was p.Gly1961Glu (3/62; 4.8%), presenting a lower frequency
than other European populations.
10 This mutation was found in
three STGD patients, two of them presenting at least one
putative null mutation (c.1030insT and p.Gln2187X), who
presented symptoms at the age of 24–25 years. Thus, we could
suspect a moderate effect for the p.Gly1961Glu allele, as
previously reported.
7
In relation to null alleles, the most frequent mutation was
c.3211insGT, identified in four independent STGD families out
of 31 (6.4%). In two of these cohorts (ARDM-125 and ARDM-
158), the second mutated allele was found by dHPLC
(p.KNLFA1876dup and c.4537delC, respectively). In both
patients, first symptoms of the disease appeared at the age of
9 years old. Nevertheless, in patients from families ARDM-165
and ARDM-167, in whom the second disease-associated allele
was not detected, the age of onset of the disease was at the third
decade of life (table 1). Therefore, we speculate that the
second—not yet detected—mutation might be of a moderate
effect, as the disease started later in life. The c.3211insGT allele
has been previously described in other studies.
17–19. Rozet et al
17
reported two STGD patients who were compound heterozy-
gous for the c.3211insGT allele and another sequence change,
whose age of onset was before 12 years old.
17 In other
population study performed by Briggs et al,
18 two STGD
patients harbouring the heterozygous c.3211insGT allele were
described. These probands presented reduced central visual
acuity before the age of 30. Interestingly, Paloma et al
19
described one CRD case, compound heterozygous for the
c.3211insGT and p.Arg212Cys variants, showing symptoms at
the age of 9. Considering these previously reported genotype–
phenotype correlations, together with the genetic and clinical
findings described in our Spanish patients, we could hypothesise
that the c.3211insGT variant is predominantly associated with
STGD, while the second mutated allele might have a modulat-
ing effect on the patient’s phenotype.
Figure 3 Family pedigrees, all diagnosed as having Stargardt disease except for family ARDM-247 whose proband presents a cone–rod dystrophy
phenotype. The family number is shown above each pedigree. Probands are indicated with an arrow.
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identified. The patient from family ARDM-125 presented the
novel p.KNLFA1876dup, located at the second transmembrane
region of the ABCR protein, while the patient from family
ARDM-158 harboured the frameshift c.4537delC variant that
causes a premature stop codon 12 amino acids downstream.
Nevertheless, as the c.3211inGT, p.KNLFA1876dup and
c.4537delC are null alleles, and some patients presented
symptoms early in life (9 years), we cannot rule out that they
could develop a more severe phenotype (arCRD) in the future.
Indeed, a similar situation has been previously reported in one
Spanish patient homozygous for the c.2888delG allele,
20 whose
clinical phenotype changed from STGD (age of onset 10 years)
to arCRD (age of diagnosis 26 years), during the course of the
study.
Two novel splice-site alterations were described, IVS21-
2A.T (ARDM-90) and IVS38+5G.A (ARDM-181). Both
patients presented STGD phenotype, and the age of onset of
the disease corresponded to the first and second decade of life,
respectively. In these cases, the total inactivation of the splice
site is unlikely, although these changes could alter the splicing
of corresponding exon, creating cryptic sites, thus producing a
longer protein.
21
In two patients diagnosed as having arCRD and arRP
phenotypes respectively, we identified the missense
p.Val1433Ile mutation, located in the second transmembrane
domain. This sequence change has been previously associated
with age-related macular degeneration (AMD)
7 and has also
been reported in one arCRD patient, although it was questioned
whether the nature of this amino acid change was pathological
or not.
22 We investigated this change further in the Spanish
control population, and it was not found in 124 ethnically
matched chromosomes, thus suggesting a pathogenic effect.
Family RP-959 was previously analysed by the genotyping
microarray, and the p.Ile156Val allele was detected.
20 This
variant has been associated with the STGD phenotype. In the
affected individual, the second mutated allele was not found by
dHPLC. Segregation analysis of the mutation within the family
did not allow this gene to be excluded. Thus, the presence of RP
phenotype and this mutation could be explained because the
second mutation would be a severe allele or would be due to
fortuitous association. Moreover, in the RP-773 and RP-1058
families, it was not possible to detect the second mutated allele,
so the implication of mutations in this gene in the development
of RP is still not clear as was previously reported.
20
To establish the nature of the three non-reported changes
located in the introns, we used a bioinformatics tool to analyse
and compare the wild type and mutated sequences. The results
demonstrated that these variants probably did not modify the
splicing process.
By MLPA analysis, no deletions or duplications were found in
patients. Indeed, it has been suggested that these alterations
contribute to only a small fraction of disease-associated alleles
for ABCA4.
23
The genotyping microarray is a comprehensive screening tool
for genetic variation in patients with ABCA4-associated retinal
pathology with a high reliability. Despite the relative small
number of families, a huge number of ABCA4 disease-associated
alleles were identified, representing an increment of 4% of novel
variants described in this gene, as ,500 sequence changes have
been described so far. To the best of our knowledge, this
optimal screening strategy represents extensive mutational
spectrum identification in Spanish patients with ABCA4-
associated phenotypes.
Moreover, these new mutations could be added to the new
versions of the ABCR400 microarray, thus increasing the
detection and validity of the array. The combination of these
three different techniques of screening (microarray, dHPLC and
MLPA) allowed us to reach a complete diagnosis of 14 of 31
patients with only one mutant allele identified, because of the
detection of the second disease-associated allele with by dHPLC.
In addition, it is probable that a great number of mutations
might reside in parts of the gene (eg, the promoter region or the
introns) that have not yet been identified.
Given an estimated prevalence of STGD (1:10 000), the
Hardy–Weinberg equilibrium would indicate that the hetero-
zygous state can be expected in about 1/50.
24 So many variants,
such as p.Val552Ile, could be really a mutation found in normal
population. Thus, expression analysis could be an interesting
tool with which to discriminate the pathological effect of these
changes.
Screening of increasingly large numbers of patients from
distinct populations would help to determine whether this
broad spectrum of mutations can be explained by ethnic
differences or is an indicator of extensive allelic heterogeneity
of ABCA4 in Stargardt disease and other retinal diseases. Follow-
up of patients, especially those presenting an early onset of the
disease and harbouring severe ABCA4 mutations, would help in
performing accurate genotype–phenotype correlations and in
further characterisation of pathological alleles.
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